AU2025204382A1 — Methods of treating disease with levoketoconazole

USPTO Abstract

#$%^&*AU2025204382A120250703.pdf##### Abstract The present invention relates to a method of treating hypercortisolism in a subject with Cushing’s syndrome, comprising administering a therapeutically effective amount of levoketoconazole, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject also has type 2 diabetes mellitus and is also being co-administered a therapeutically effective amount of metformin, or a pharmaceutically acceptable salt thereof; wherein the therapeutically effective amount of levoketoconazole, or a pharmaceutically acceptable salt thereof, is determined via a titration scheme, and wherein the therapeutically effective amount of metformin, or a pharmaceutically acceptable salt thereof, is reduced relative to a subject who is not being administered levoketoconazole, or a pharmaceutically acceptable salt thereof. Abstract The present invention relates to a method of treating hypercortisolism in a subject with Cushing's syndrome, comprising administering a therapeutically effective amount of levoketoconazole, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject also has type 2 diabetes mellitus and is also being co-administered a therapeutically effective amount of metformin, or a pharmaceutically acceptable salt thereof; wherein the therapeutically effective amount of levoketoconazole, or a pharmaceutically acceptable salt thereof, is determined via a titration scheme, and wherein the therapeutically effective amount of metformin, or a pharmaceutically acceptable salt thereof, is reduced relative to a subject who is not being administered levoketoconazole, or a pharmaceutically acceptable salt thereof.